Proceeds to support the clinical development of the eShunt System including the recently approved pivotal trial in Normal Pressure Hydrocephalus

继续支持eShunt系统的临床开发，包括最近批准的常压脑积水关键试验

Financing co-led by Bain Capital Life Sciences and existing investor Perceptive Xontogeny Venture Fund

由贝恩资本生命科学公司和现有投资者感知的Xontogeny风险基金共同领导的融资

BOSTON, May 13, 2024 /PRNewswire/ -- CereVasc, Inc., a clinical-stage, medical device company developing novel treatments for neurological diseases, announced today it has successfully completed the initial closing of a $70 Million Series B financing. The financing was jointly led by Bain Capital Life Sciences and existing investor Perceptive Xontogeny Venture Fund (PXV), with additional participation from other existing investors..

波士顿，2024年5月13日/PRNewswire/-CereVasc，Inc.，一家开发神经系统疾病新型治疗方法的临床阶段医疗器械公司，今天宣布，它已成功完成7000万美元B系列融资的初步关闭。此次融资由贝恩资本生命科学公司和现有投资者感知型Xontogeny风险基金（PXV）共同牵头，其他现有投资者也参与了此次融资。。

Proceeds from the financing will be used to support the clinical and regulatory development of CereVasc's eShunt System, including its upcoming STRIDE pivotal study in patients with Normal Pressure Hydrocephalus. STRIDE is a multi-center, randomized controlled trial that will assess the safety and efficacy of the eShunt System compared to the current standard-of-care ventriculo-peritoneal (VP) shunt and serve as the basis for a future Premarket Approval (PMA) submission to the FDA..

融资所得将用于支持CereVasc的eShunt系统的临床和监管发展，包括即将进行的针对正常压力脑积水患者的STRIDE关键研究。STRIDE是一项多中心随机对照试验，将评估eShunt系统与当前标准的脑室-腹膜（VP）分流术相比的安全性和有效性，并作为未来上市前批准（PMA）提交给FDA的基础。。

'We are thrilled to partner with this premier group of investors who support our vision and novel approach to bringing an innovative treatment for hydrocephalus to the market,' said Dan Levangie, Chairman & CEO of CereVasc. 'Their commitment is a testament to the clinical progress we have made with the eShunt System, and to the potential we have to transform hydrocephalus treatment.

CereVasc董事长兼首席执行官丹·莱万吉（DanLevangie）说，我们很高兴能与这批支持我们的愿景和新方法的顶级投资者合作，将创新的脑积水治疗方法推向市场他们的承诺证明了我们在eShunt系统方面取得的临床进展，以及我们必须改变脑积水治疗的潜力。

We are now well positioned to execute our pivotal clinical trial in advance of regulatory approvals.'.

我们现在处于有利地位，可以在监管部门批准之前执行我们的关键临床试验。”。

In conjunction with the financing, Evan Greif, a Vice President at Bain Capital Life Sciences, will join CereVasc's Board of Directors. 'CereVasc has a distinct opportunity to dramatically improve the care of patients with hydrocephalus. We look forward to partnering with Dan and his team to bring this potential breakthrough technology to the global market,' said Mr.

在融资方面，贝恩资本生命科学公司副总裁埃文·格雷夫（EvanGreif）将加入CereVasc的董事会CereVasc有一个明显的机会来显着改善脑积水患者的护理。他说，我们期待着与丹和他的团队合作，将这项潜在的突破性技术推向全球市场。

Greif..

格里芬。

Piper Sandler served as the Company's financial advisor for the Series B transaction.

派珀·桑德勒（Piper Sandler）担任该公司B轮交易的财务顾问。

About CereVasc, Inc.

关于CereVasc，股份有限公司。

Located in Massachusetts' healthcare hub, CereVasc, Inc., is a clinical stage, medical device company focused on the development of novel, minimally invasive treatments for patients with neurological diseases. Its initial product, the eShunt System, encompasses first-ever, groundbreaking percutaneous transvenous-transdural access to the central nervous system intended to allow the first minimally invasive treatment for communicating hydrocephalus (CH), a potential improvement to the current standard of care.

CereVasc，Inc.位于马萨诸塞州医疗保健中心，是一家临床阶段的医疗器械公司，专注于为神经系统疾病患者开发新型微创治疗方法。其最初的产品eShunt系统包括有史以来第一次突破性的经皮经静脉经硬脑膜进入中枢神经系统，旨在首次对交通性脑积水（CH）进行微创治疗，这是对当前护理标准的潜在改进。

The eShunt device concept originated from Tufts Medical Center physicians Carl Heilman, MD, Neurosurgeon-in-Chief and Chair of Neurosurgery, and Adel Malek, MD, PhD, Chief of Neurovascular Surgery and Director of Endovascular Neurosurgery. The patented eShunt System includes an endovascularly implantable cerebral spinal fluid shunt and delivery components, which are designed to treat CH without invasive surgery.

eShunt设备的概念起源于塔夫茨医学中心的医生Carl Heilman，医学博士，神经外科主任和神经外科主席，以及Adel Malek，医学博士，博士，神经血管外科主任和血管内神经外科主任。获得专利的eShunt系统包括血管内植入式脑脊液分流和输送组件，旨在治疗CH而无需进行侵入性手术。

For additional information, please visit our website at www.cerevasc.com..

有关更多信息，请访问我们的网站www.cerevasc.com。。

The eShunt® Device is an investigational device and not available for sale within or outside the United States.

eShunt®设备是一种研究设备，不可在美国境内或境外销售。

Company Contacts:

公司联系人：

DJ Cass

DJ卡斯

CereVasc, Inc.

CereVasc，股份有限公司。

djcass@cerevasc.com

djcass@cerevasc.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/cerevasc-announces-70-million-series-b-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302142922.html

查看原始内容以下载多媒体：https://www.prnewswire.com/news-releases/cerevasc-announces-70-million-series-b-financing-to-advance-its-novel-eshunt-system-for-the-treatment-of-normal-pressure-hydrocephalus-302142922.html

SOURCE CereVasc, Inc.

来源CereVasc，Inc。